JPRN-UMIN000032153已完成2 期
A phase II neoadjuvant trial of sequential nab-paclitaxel followed by 5-fluorouracil/epirubicine/cyclophosphamide (FEC) in operable breast cancer - A phase II neoadjuvant trial of sequential nab-paclitaxel followed by FEC in operable breast cancer
Yokkaichi Municipal Hospital0 个研究点目标入组 50 人开始时间: 2018年4月9日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)Known hypersensitivity to human serum alb umin 2)Concurrent, serious or uncontrolled infect ions 3)Inadequately controlled or serious history of cardiac disease 4)Confirmed symptomatic brain metastasis 5)Current pregnancy and lactation, or possib ility of pregnancy 6)Known drug allergy to any of study drugs 7)Assessment by investigator that subject un able to comply with protocol
研究者
相似试验
招募中
2 期
A phase II neoadjuvant trial of sequential nab-paclitaxel followed by dose dense epirubicine/cyclophosphamide (ddEC) in operable breast cancerbreast cancerJPRN-UMIN000041509Breast Surgery, Yokkaichi Municipal Hospital20
招募中
2 期
Phase 2 study of neoadjuvant tri-weekly Nab-paclitaxel and Trastuzumab followed by FEC(5-FU/epirubicin/cyclophosphamide) in patients for HER2 positive breast cancer.JPRN-UMIN000010579Department of gastroenterologic and breast surgery Kanazawa University,School of Medicine35
进行中（未招募）
2 期
eoadjuvant bevacizumab and temozolomide chemotherapy for malignant gliomaJPRN-jRCT1031180233Tamura Ryota15
未知
2 期
An exploratory phase II study of neoadjuvant bevacizumab and temozolomide chemotherapy for patients with newly diagnosed malignant gliomamalignant gliomaJPRN-UMIN000025579Keio university school of medicine15
进行中（未招募）
不适用
Phase II trial assessing neoadjuvant therapy with FEC 100 followed by Taxotere® (docetaxel) plus Vectibix® (panitumumab) in patients with operable, HR and Her-2 negative breast cancer. TVA study. - TVA studyRH- and Her2- operable breast cancer, in neoadjuvant situationMedDRA version: 9.1Level: LLTClassification code 10022882Term: Invasive ductal breast cancerEUCTR2009-012853-39-FRCentre Jean Perrin